SCHEMBL8943403

SCHEMBL8943403

OC[C@@H]1CCC[C@@H]1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4141863 1.00
SCHEMBL924500 1.00
SCHEMBL1802277 1.00
SCHEMBL130804 0.92 TDP1 (0.50)
SCHEMBL129425 0.92 TDP1 (0.50)
SCHEMBL33424 0.92 TDP1 (0.50)
SCHEMBL44781 0.92 TDP1 (0.50)
SCHEMBL130805 0.92 TDP1 (0.50)
SCHEMBL12816270 0.92 TDP1 (0.50)
SCHEMBL8943002 0.89 TDP1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10167302-B2 Phosphonate nucleosides useful in the treatment of viral diseases UNIVERSITY COLLEGE CORK (IE) 2019-01-01 US disclosed
US-20170218001-A1 PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2017-08-03 US disclosed
US-20170218001-A1 PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2017-08-03 US disclosed
WO-2015177351-A1 PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES UNIVERSITY COLLEGE CORK (IE) 2015-11-26 WO disclosed
US-7166754-B2 Methods and compositions for enantioselective oxidation reactions CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-01-23 US disclosed
US-7166754-B2 Methods and compositions for enantioselective oxidation reactions CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-01-23 US disclosed
EP-0614457-B1 LEUKOTRIENE-B 4? DERIVATIVES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS SCHERING AG (DE) 1996-08-21 EP disclosed
US-5502075-A Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 1996-03-26 US disclosed
EP-0529022-B1 NEW LEUKOTRIENE B 4? DERIVATIVES, METHOD FOR PREPARING THEM AND THEIR USE AS DRUGS SCHERING AG (DE) 1995-09-27 EP disclosed
US-5414016-A New leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 1995-05-09 US disclosed
EP-0614457-A1 LEUKOTRIENE-B 4? DERIVATIVES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS. SCHERING AG (DE) 1994-09-14 EP disclosed
WO-1993011105-A1 LEUKOTRIENE-B4 DERIVATIVES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1993-06-10 WO disclosed
EP-0529022-A1 NEW LEUKOTRIENE B 4? DERIVATIVES, METHOD FOR PREPARING THEM AND THEIR USE AS DRUGS. SCHERING AG (DE) 1993-03-03 EP disclosed
WO-1992016504-A1 NEW LEUKOTRIENE B4 DERIVATIVES, METHOD FOR PREPARING THEM AND THEIR USE AS DRUGS SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1992-10-01 WO disclosed